Novartis agreed to acquire clinical-stage biopharmaceutical maker Tourmaline Bio Inc. in an all-cash deal worth around $1.4 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results